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Abstract 
Introduction: At present, enterosorbents based on mineral raw materials are in high 
demand among the population. However, there are no enterosorbents on the Russian 
pharmaceutical market on the basis of domestic mineral raw materials. 
Objectives: to study the pharmacological activity of enterosorbent based on 
montmorillonite of Russian origin under experimental conditions. 
Methods: The methodological approach was based on the implementation of a complex of 
theoretical, pharmacological, toxicological, histological, biochemical, statistical methods. 
Models of experimental diarrhea, acute and toxic liver damage, acute experimental 
pancreatitis were selected. 
Results and discussion: Enterosorbent based on montmorillonite Crim_04 has a dose-
dependent antidiarrhoeal effect, which is manifested in an increase in the time of onset of 
diarrhea from 50.4% to 82.6% with various models of diarrhea, a reduction in the number 
of defecations from 50.4% to 64.4% liquid in them. Enterosorbent on the basis of 
montmorillonite has a high sorption activity to E.coli enterotoxin, inhibiting the outflow of 
fluid into the luminal cavity by 95.1%. In addition, the use of enterosorbent Crim_04 
significantly improves biochemical indices in the blood serum of rats when modeling acute 
and chronic liver damage and acute pancreatitis. 
Conclusion: The enterosorbent under the Crim_04 cipher has a dose-dependent anti-
diarrhea, detoxification activity, high sorption activity for E.coli enterotoxin, high 
therapeutic efficacy in experimental pancreatitis, most pronounced at a dose of 3320 mg / 
kg. It can be recommended for further complex toxicological studies and clinical trials. 
Keywords: enterosorbents, montmorillonite, preclinical studies, diarrhea, intoxication. 
 
Introduction 
The pathological conditions associated with 
the syndrome of endogenous intoxication, as well 
as exogenous intoxications with salts of heavy 
metals, toxins of fungi and bacteria are extremely 
common today. This is due to the growth of 
atmospheric and aqueous pollutants, 
contamination of food and drinking water by 
bacterial and endotoxic agents [1, 2]. In Russia, 
about 90 thousand poisonings are annually 
registered [3]. One of the most common diseases, 
having water or food origin, is diarrhea. 
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According to WHO, diarrhea is one of the leading 
causes of death in the world, ranking 8th in the 
frequency of causes of death. In 2015, 1.39 
million people died of diarrheal diseases, most of 
them children. In 2013, diarrhea was the second 
most frequent cause of death of children. 
Annually more than 1.7 billion cases of diarrhea 
are registered in the world. These statistics relate 
mainly to countries with low and medium-low 
incomes [4, 5]. The syndrome of endogenous 
intoxication is also accompanied by exogenous 
intoxications and diseases of internal organs, for 
example hepatitis, acute pancreatitis [6, 7, 8]. 
One of the most common, effective and 
accessible methods of detoxification of the body 
is the method of enterosorption [9, 10, 11, 12]. Of 
particular interest in this regard is mineral raw 
materials, in particular montmorillonite. 
Montmorillonite, due to its properties [13, 14, 15], 
has an antacid [16], antidiarrhoeal [17, 18, 19], 
cytomycoprotective [20], anti-inflammatory and 
anti-cytokine [21], high sorption activity against 
bacterial toxins [22, 23, 24, 25], salts of heavy 
metals [26], aflatoxin [24, 27], herbicides [28] for 
oral administration. Enriched with silver 
nanoparticles, montmorillonite has a bactericidal 
effect [22, 23, 24]. The structure, physical and 
chemical properties, mechanisms of sorption of 
toxins and xenobiotics on the surface of 
montmorillonite have been studied quite 
thoroughly [13, 29, 30]. 
Enterosorbent preparations based on mineral 
raw materials, mainly smectite dioctahedral, are 
in high demand among the population of Russia, 
far outstripping other enterosorbents [30, 31]. At 
the moment on the Russian pharmaceutical 
market there are 4 medicines with enterosorption 
activity on the basis of smectite minerals. 
However, they are all made from foreign 
substances. The development of medicines based 
on domestic substances is an urgent task for the 
public health and pharmaceutical industry and is 
consistent with the "Pharma Strategy-2020" [32]. 
Degree of elaboration of the research topic. 
The sorption properties of clay minerals have 
attracted the attention of scientists for the last 
half-century [33, 34]. Over the past decade, many 
works on structure, physicochemical properties, 
experimental and clinical studies of the 
effectiveness of smectites, including 
montmorillonite, have been published [35, 36]. 
To date, there are several drugs based on smectite 
clay minerals. These are mainly preparations 
based on smectite dioctahedral. However, the 
clinical efficacy of the montmorillonite calcium 
preparation in the treatment of aflatoxicosis 
(NovaSil, the manufacturer of Engelhard 
Chemical Corporation, USA) has been 
thoroughly investigated. However, there is no 
enterosorbent based on layered aluminosilicates 
produced on the basis of domestic raw materials 
on the Russian pharmacological market. To solve 
this problem, it is necessary to study 
montmorillonite of Russian origin with high 
sorption activity at the preclinical level. 
Objectives: to study the pharmacological 
activity of enterosorbent on the basis of 
montmorillonite under experimental conditions. 
Materials and methods of research 
The work was performed on the basis of 
Belgorod State University in the preclinical 
research laboratory of the Center for Preclinical 
and Clinical Studies on 430 white mature rats, 
Wistar males (weight 200±20 g) and 460 
laboratory mice of both sexes (weight 25±2 g). 
All stages of the research were carried out in 
accordance with the requirements of GOST 
ISO/IEC 17025-2009, GOST R ISO 5725-2002 
and the "Rules of Laboratory Practice" approved 
by Order No. 708n of the Ministry of Healthcare 
and Social Development of the Russian 
Federation of August 23, 2010, in compliance 
with the "European Convention for the Protection 
of Vertebrates, used for experiments or for other 
scientific purposes "[Directive 2010/63 / EU]. 
Vivisection was carried out in accordance with 
the principles of the "European Convention for 
the Protection of Vertebral Animals Used for 
Experimental and Other Scientific Purposes." 
CETS No. 123 ". 
Object of study 
The object of the study was a prototype of 
enterosorbent based on montmorillonite of the 
Crimean deposit under the laboratory code 
Crim_04, provided by the company 
"Krympharmmamed". The experimental sample 
of enterosorbent Crim_04 is a powder from a 
yellowish- or grayish-white color to a grayish or 
brownish-yellow color with the smell of vanillin. 
The mass fraction of montmorillonite is 62.4%, 
silver – 0.15%. The size of the most common 
particles in the suspension is 7.08 μm. 
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Comparison preparations: Enterosorbent 
"Smecta" (Beaufuor Ipsen Industrie, France) and 
loperamide ("Janssen-Cilag", France). 
Methods of research 
A study of the acute toxicity of 
montmorillonite-based enterosorbent under the 
laboratory code Crim_04 was carried out on 
laboratory mice of both sexes weighing 25±2 g in 
accordance with the "Guidelines for preclinical 
drug research" [37, 38]. 
Calculation of doses was carried out 
individually for each animal in mg / kg. The 
calculation of the optimal therapeutic dose was 
carried out using tables of dose recalculation, 
taking into account the average therapeutic dose 
of the drug "Smecta" for humans, the average 
weight of a person is 70 kg, the average weight of 
the rat is 200 g, the average mouse weight is 25 g 
[38]. As a result, the optimal therapeutic dose for 
the rat was 770 mg/kg, for the mouse – 1660 
mg/kg. 
Laboratory mice were used to model acute 
diarrhea. Acute diarrhea was modeled by 
intraperitoneal single administration of serotonin 
hydrochloride (5-hydroxytryptamine 
hydrochloride, 5-HT) at a dose of 0.32 mg / kg 
(n=20 animals) [39]. In the modeling of diarrhea 
induced by castor oil, castor oil was injected 
intragastrically at a dose of 0.5 ml per individual 
(n=20 animals) [40], magnesium sulfate (MgSO4) 
was used intragastrically at a dose of 2 g/kg to 
model MgSO4-induced diarrhea [40] (n=20 
animals) [41]. Serotonin hydrochloride was used 
30 minutes after intragastric administration of 
enterosorbents and loperamide. Castor oil and 
magnesium sulfate were used 30 minutes prior to 
administration of the investigational 
pharmacological agents. In the group of intact 
animals 0.9% sodium chloride solution 10 ml/kg 
(n=20 animals) was used. 
In the experimental groups, the aqueous 
suspensions of enterosorbents Crim_04 were 
injected single times in animals at doses of 880 
mg/kg, 1660 mg/kg, 3320 mg/kg and Smecta in a 
dose of 1660 mg/kg, loperamide at an effective 
dose of 10 μg/kg, taking into account the 
recalculation of doses from the average 
therapeutic daily dose for humans. In the control 
group, the animals received an equivalent volume 
of 0.9% sodium chloride solution. 
After modeling the pathology, the time of 
onset of diarrhea, the number of defecations, and 
the weight of stool for 4 hours were taken into 
account. To calculate the severity of inhibition 
(SI) diarrhea used formula (1). 
    %100% 



 
Dk
DiDk
SI  (1), 
where Dк – the number of wet and liquid 
defecations in the control group, Di – the number 
of wet and liquid defecations in the study groups. 
Calculation of the coefficient of severity of 
diarrhea (CSD) was carried out with the help of a 
scale scale for assessing the consistency of stool 
mass: 1 point – normal excrement, 2 – semi-
liquid, wet defecation, 3 points – liquid 
defecation. The indicator was calculated using 
formula (2). 
D
LSN
CSD



)321(
 (2), 
where N is the amount of normal excrement, 
S is the number of semi-liquid excrement, L is the 
amount of liquid excrement, and ΔD is the total 
number of defecations during observation. 
Stressed defecations at the beginning of the 
experiment were not taken into account when 
calculating the total number of fecal outcrops 
during the experiment. 
After 4 hours of observation, the animals 
were anesthetized from the experiment. For 
pathomorphological examination, the small 
intestine sites were taken from animals [42]. 
Wistar male rats were used to model isolated 
gut loop. Before the experiment, the animals 
starved for 1 day with free access to water. 
Chloral hydrate 300 mg/kg was used for 
anesthesia intraperitoneally. After epilation of the 
hair on the abdomen, a laparotomy of 2.5 cm was 
carried out. At a distance of 5 cm from the 
stomach, the first ligation was applied to the 
intestine with a constant irrigation of 0.9% 
sodium chloride solution. Then, in steps of 2.5 
cm, ligatures were applied to the intestine to 
create isolated loops, avoiding ligation of vascular 
feeding beams. A 0.9% sodium chloride solution 
was injected into the lumen of the first two loops 
in a volume of 0.2 ml (internal control, intact 
loops), the rest – thermolabile cholera-like E.coli 
enterotoxin (TCET, Sigma-Aldrich, USA) at a 
dose of 2 μg/loop in a volume of 0.2 ml [43]. 
The aqueous suspensions of Crim_04 and 
Smecta® at a concentration of 50 mg/ml, 100 
mg/ml, 200 mg/ml were introduced into the lumen 
of the intestine loops with a toxin in a volume of 
0.2 ml. The concentration of enterosorbents in the 
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suspension was determined empirically, given the 
permeability of the suspension through the needle 
of the insulin syringe. In the control group, 2 μg 
of enterotoxin and 0.2 ml of 0.9% sodium chloride 
solution. Water suspensions of enterosorbents and 
0.9% solution of sodium chloride were introduced 
into the lumen of the gut simultaneously with 
E.coli enterotoxin. The anterior abdominal wall 
was sutured layer by layer. Animals were placed 
in individual cells. After 4 hours, the animals were 
removed from the experiment. The degree of 
toxin exposure was assessed by the dilatation 
index, which was calculated from formula (3). 
L
MID   (3), 
where M is the weight of the loop in mg, L is 
its length in cm. 
The severity of the inhibition of fluid outflow 
into the lumen of the intestinal loops was 
determined by the formula (4). 
%100
2
)12( 





SI  (4), 
where Δ1 is the difference between the loop 
ID with toxin, and the control loops in the 
experimental animals; Δ2 – the same in the 
control group. At the same time, the fluid outlet 
level in the control loops was assumed to be 
100%. For the morphological study, the sites of 
the small intestine were taken from the animals. 
To model acute toxic damage to the liver, 
male rats were intraventrically injected with 
tetrachloromethane in an oily solution at a 
concentration of 1:1 at a dose of 0.5 ml / kg of 
active ingredient daily for six days (n=20 
animals). On the seventh day, animals were 
intraperitoneally injected with S.thyphi 
lipopolysaccharide at a dose of 20 μg/kg [44]. 
To simulate chronic toxic damage to the liver 
intragastrically male rats were injected with 
carbon tetrachloride (CTC)in oily solution at a 
dose of 0.5 ml/kg of active ingredient daily for 20 
days (n=20 animals). At 6, 13, and 20 days, 
animals were intraperitoneally injected with 
S.thyphi lipopolysaccharide (LPS) at a dose of 20 
μg/kg [44]. Animals in intact groups received 
0.9% solution of sodium chloride orally (n=20 
animals). 
On the third day, the animals of the 
experimental groups received the enterosorbent 
under the Crim_04 cipher at doses of 385 mg/kg, 
770 mg/kg and 1500 mg/kg and the Smecta 
preparation at a dose of 770 mg/kg as aqueous 
suspensions intragastrically 12 hours after the 
administration of carbon tetrachloride  
n=20 animals). 
In both series of experiments, the physical 
condition of the animals was monitored. After 
excretion, the animals were taken blood for 
biochemical studies and liver tissue for 
morphological investigation. The activity of 
alanine aminotransferase (AlAT, U/l), aspartate 
aminotransferase (AsAT, U/l), alkaline 
phosphatase (AP, U/l), urea (mmol/l), total 
bilirubin (μmol/L), creatinine (μmol/L) in the 
blood serum. 
Experimental acute pancreatitis was modeled 
by intraperitoneal single administration of a 
solution of L-arginine in phosphate buffer (pH = 
6.8) at a dose of 1,5 g/kg (n=20 animals) to male 
rats. In the intact group, the animals received a 
0.9% solution of sodium chloride orally (n=20 
animals). Enteric sorbent under the laboratory 
cipher of Crim_04 in doses of 385 mg/kg, 770 
mg/kg, 1500 mg/kg in the form of aqueous 
suspensions were administered concomitantly 
with L-arginine and then every 4 hours, 4 times in 
total to rats intragastrically (n=20 animals). The 
rats in the control group were intragastrically 
injected with an equivalent volume of 0.9% 
sodium chloride solution. 
The mortality and survival of animals in 
groups for the first 24 hours was assessed. 
Animals were withdrawn from the experiment 
under anesthesia 72 hours after the induction of 
acute pancreatitis. Animals were collected blood 
for biochemical research. The following 
parameters were studied: serum amylase activity 
(U/l), aspartate aminotransferase (AsAT, U/l), 
alanine aminotransferase (AlAT, U/l), glucose 
content (mmol/l), triglycerides (TG, mmol/l). 
Pancreatic tissue was taken for 
pathomorphological examination [45]. 
Biochemical research 
When breeding animals from the experiment, 
the blood was taken into test tubes with sodium 
heparin as an anticoagulant for. Biochemical 
indicators were determined using standard 
reagent kits of Diakon JSC (Russia) on a 
biochemical analyzer URIT-800 Vet (URIT 
Medical Electronic Co., Ltd., China). 
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Morphological investigation 
The tissues were fixed in a 10% solution of 
neutral formalin, followed by pouring into 
paraffin. From the resulting blocks, sections of 5-
7 microns thick were prepared. The staining was 
performed with hematoxylin-eosin. Microscopic 
examination was carried out on a micrometer 
"Mikmed-6" (LOMO, St. Petersburg), image 
analysis was carried out using the program 
"Micro-analysis Pro" (LLC LOMO-
Microsystems, St. Petersburg). 
Statistical analysis 
Statistical processing of data was carried out 
using the Microsoft Excel 2010 and 
STATISTIKA 6.0 software packages for 
Windows. The average values of the indicators 
studied are given in the form (M±m), where M is 
the arithmetic mean and m is the standard error of 
the mean. To analyze the differences between the 
groups, the t-test of the Student was used. The 
difference of the compared indicators for p <0,05 
was considered reliable. 
Results and discussion 
Investigation of the dose-dependent nature 
of antidiarrhoeal activity of enterosorbent based 
montmorillonite under the laboratory code 
Crim_04 on various models of acute diarrhea. 
It was found that an intraperitoneal injection 
of serotonin hydrochloride at a dose of 0.32 mg / 
kg causes diarrhea in 100% of the animals for 15 
minutes, which is manifested by a significant 
increase in the number of defecations with a 
predominance of watery stools. 
 
Fig. 1A. Dose-dependent influence of enterosorbent under the Crim_04 cipher for the time of onset of 
serotonin-induced diarrhea in mice (minutes). 
Note: + – for p <0.05 in comparison with the group of intact animals; * – at p <0.05 in comparison with the control 
group; a – p <0.05 in comparison with the group Crim_04 in a dose of 880 mg/kg; b – p <0.05 in comparison with 
the group Crim_04 in a dose of 1660 mg/kg; # – p <0.05 in comparison with the group of loperamide 
 
As can be seen from Fig. 1A the use of 
enterosorbent under the code Crim_04 
significantly increased the onset of diarrhea. 
Diarrhea occurred more than 5.5 times later than 
in the control group. This effect was most 
pronounced when using enterosorbent in a dose of 
3320 mg/kg. 
The use of enterosorbent under the Crim_04 
cipher reduced the amount of defecations in mice 
when modeling serotonin-induced diarrhea. It 
was found that the use of enterosorbent Crim_04 
at a dose of 3320 mg/kg caused an inhibition of 
the development of diarrhea by 52.1%, which is 
reflected in a decrease in the number of wet and 
liquid defecations in comparison with the control 
group. This result is significantly higher than in 
groups where the enterosorbent was used at doses 
of 880 mg/kg and 1660 mg/kg (26.7% and 35.9%, 
respectively). For Smekta and loperamide, this 
indicator was 34.8% and 73.8%, respectively 
(Fig. 1B). 
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Fig. 1B. Dose-dependent influence of enterosorbent under the code Crim_04 on the number of 
defecations in serotonin-induced diarrhea in mice (number). 
Note: + – for p <0.05 in comparison with the group of intact animals; * – at p <0.05 in comparison with the control 
group; a – p <0.05 in comparison with the group Crim_04 in a dose of 880 mg/kg; b – p <0.05 in comparison with 
the group Crim_04 in a dose of 1660 mg/kg; # – p <0,05 in comparison with the group of loperamide 
 
With intragastric administration of 
enterosorbent under the code Crim_04, a decrease 
in the fluid content in the feces was observed, 
defecation was predominantly moist. Most of this 
effect is expressed in groups of animals receiving 
the enterosorbent Crim_04 at a dose of 3320 
mg/kg (Figure 1C). 
 
Fig. 1C. Dose-dependent influence of enterosorbent under the code Crim_04 on the consistency of feces 
in serotonin-induced diarrhea in mice (cond. 
Note: + – for p <0.05 in comparison with the group of intact animals; * – at p <0.05 in comparison with the control 
group; a – p <0.05 in comparison with the group Crim_04 in a dose of 880 mg/kg; b – p <0.05 in comparison with 
the group Crim_04 in a dose of 1660 mg/kg; # – p <0,05 in comparison with the group of loperamide 
 
The indices of the enterosorbent under the 
code Crim_04 in the average therapeutic dose of 
1660 mg/kg did not significantly differ from the 
effect of dioctahedral smectite in the same dose. 
At the same time, the enterosorbent under the 
code number Crim_04 and the "Smecta" 
preparation were significantly inferior to 
loperamide by the time of onset of diarrhea, the 
total number of defecations and the fluid content 
in the stool. 
Morphological study revealed that in the 
animals of the control group macroscopically the 
intestinal mucosa is swollen, edematic, pink-gray 
in color, and is hyperemic in separate areas. The 
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surface of the mucous membrane is covered with 
a slightly turbid, semi-liquid mucus, which is well 
washed away with water. 
Microscopically the mucosa is edematous. 
Defined shortening and deformation of the villi. 
At the ends of some villi, the epithelium is 
squashed, exposing its own plate of mucosa. 
Defined hypertrophy of crypts is determined. The 
blood vessels of the mucosa and submucosa are 
full-blooded. Muscular and serous intestinal 
membranes are unchanged. In the lumen of the 
intestine, a large amount of mucus (Fig. 2B). 
These changes were not characteristic of intact 
animals (Fig. 2A). 
In groups of animals that received 
enterosorbent under the laboratory cipher of 
Crim_04 at doses of 3320 mg/kg, the pathological 
changes in the small intestine consisted of a slight 
edema of the mucous membrane. Plots of 
hyperemia of the mucosa was not observed. The 
phenomena of slimming of the epithelium were 
minimal, there were no sites of exposure of the 
lamina propria of the mucous membrane. The 
blood supply to the vessels of the mucosa and the 
submucosal layer was moderate. Muscular layer 
and serosa without pathological changes (Fig. 
2D). 
 
Fig. 2. Histological structure of the ileum in mice against the background of modeling serotonin-induced 
diarrhea (microphot × 100). 
Note: A – intact animals; B – control group; C – enterosorbent Crim_04 in a dose of 1660 mg/kg;  
D – enterosorbent Crim_04 in a dose of 3320 mg/kg; E – Enterosorbent "Smecta" 1660 mg/kg;  
F – loperamide 10 μg/kg. Okr. hematoxylin and eosin 
 
In the control group with simulation of 
serotonin-induced diarrhea, a decrease in the 
height of the villi was 1.4 times, an increase in the 
width of the villi at the base by 1.4 times and the 
depth of the crypts by 1.2 times in comparison 
with intact animals. The use of enterosorbent 
under the code Crim_04 at a dose of 3320 mg/kg 
significantly improved the histological picture of 
the small intestine, bringing the morphometric 
parameters closer to the level of intact animals 
(Fig. 3). 
D E F 
В А С 
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Fig. 3. Influence of the enterosorbent under the Crim_04 cipher on the ratio of the length of the villi to the 
width of the villi and the length of villi to the depth of crypt in the small intestine of mice when 
simulating serotonin-induced diarrhea (conv. Units). 
Note: * – for p <0.05 in comparison with the group of intact animals; ** – at p <0.05 in comparison with the 
control group; a – p <0.05 in comparison with the group Crim_04 in a dose of 880 mg/kg 
 
Similar results were obtained in the modeling 
of castor-induced diarrhea and MgSO4-induced 
diarrhea. So the use of the enterosorbent Crim_04 in 
a dose of 3320 mg/kg on the model of diarrhea 
induced by castor oil increased the time of onset of 
diarrhea from 42.7±2.9 minutes in the control group 
to 124.2±5.4 minutes, reduced the total number of 
defecations by 64.4%, and significantly affected the 
consistency of defecations, significantly increasing 
their density from 2.58±0.02 to 1.54±0.01 points. 
With the application of enterosorbent 
Crim_04 at a dose of 3320 mg/kg on the model of 
MgSO4-induced diarrhea, the time of onset of 
diarrhea increased from 62.8±1,2 minutes in the 
control group to 126.8±4.7 minutes, reducing the 
total number of defecations by 50.5 % and 
significantly affected the consistency of 
defecations, significantly increasing their density 
from 2.79±0.04 to 1.81±0.04 points. 
Investigation of the sorption activity of 
enterosorbent on the basis of montmorillonite 
under the laboratory cipher of Crim_04 on the 
model of an isolated loop of the small intestine. 
The dose-dependent nature of the sorption 
activity of enterosorbent based on 
montmorillonite under the laboratory cipher of 
Crim_04 with respect to the thermolabile cholera-
like enterotoxin E.coli in comparison with the 
"Smecta" preparation on the isolated loop model 
in rats is shown in Fig. 4. 
 
Fig. 4. Influence of the enterosorbent under the Crim_04 cipher in comparison with the Smecta 
preparation on the dilatation index on the isolated bowel loop model (mg/cm). 
Note: * – for p <0.05 in comparison with the control group; ** – at p <0.05 in comparison with TCET; a – at p 
<0,05 in comparison with enterosorbents in a dose of 50 mg/ml; b – at p <0,05 in comparison with enterosorbents 
in a dose of 100 mg/ml 
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It is established that the enterosorbent on the 
basis of montmorillonite under the laboratory 
cipher of Crim_04 has a high sorption activity 
with respect to the thermolabile cholera-like 
E.coli enterotoxin on the model of an isolated 
intestinal loop. This action is manifested by 
preventing the development of increased fluid 
formation in the lumen of the gut (Fig. 5). 
 
 
 
Fig. 5. The dose-dependent effect of the enterosorbent under the Crim_04 cipher in comparison with the 
Smecta preparation on the severity of the inhibition of fluid flow into the lumen of the gut  
on the model of the isolated bowel loop (%). 
Note: * – at p <0,05 in comparison with enterosorbents in a dose of 50 mg/ml; ** – at p <0,05 in comparison with 
enterosorbents in a dose of 100 mg/ml 
 
  
In this case, a clear dose-dependent effect is 
established, most pronounced when using an 
aqueous suspension of enterosorbent at a 
concentration of 200 mg/ml. This is also 
manifested by an improvement in the 
morphological pattern of the small intestine. The 
use of enterosorbent under the cipher of Crim_04 
prevents the development of hypertrophy of 
crypts, swelling of the villi and increased mucosal 
epilation of the mucous membrane. 
Morphometric indices when using enterosorbent 
under the Crim_04 cipher are close to the level of 
intact loops. 
The study of the detoxification activity of 
enterosorbent on the basis of montmorillonite 
under the laboratory code Crim_04 on models 
of acute and chronic toxic damage of the liver. 
The dose-dependent character of the 
influence of enterosorbent on the basis of 
montmorillonite under the laboratory code 
Crim_04 on the activity of liver enzymes, 
biochemical parameters of blood serum in 
comparison with the "Smecta" preparation for 
modeling acute toxic damage of the liver is shown 
in Fig. 6A, 6B, 6C, 6D, 6E. 
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Fig. 6A. Influence of application of enterosorbent under the code Сrim_04 on the activity of AsAT and 
AlAT in modeling acute toxic liver damage in rats (U/l). 
Note: ** – p <0.05 – in comparison with the control; * – p <0.05 – in comparison with intact 
 
When using enterosorbent under the 
laboratory cipher of Crim_04 on the model of 
acute CTC-induced toxic liver damage, the 
activity of AsAT and AlAT in the blood plasma 
of animals decreased, the de Ritis coefficient 
decreased from 1.4 in the negative control group 
to 2.5 in the group using the enterosorbent 
Crim_04 (Fig. 6A). 
 
 
Fig. 6B. Effect of the use of enterosorbent under the code Сrim_04 on the activity of alkaline phosphatase 
in the blood of rats when modeling acute toxic damage to the liver (U/l). 
Note: ** – p <0.05 – in comparison with the control; * – p <0.05 – in comparison with intact 
 
 
Also, the introduction of an enterosorbent 
under the Crim_04 cipher caused a decrease in the 
activity of alkaline phosphatase (Figure 6B), 
levels of urea (Figure 6C), creatinine (Figure 6D) 
and total bilirubin (Figure 6E) in the plasma of 
experimental animals. 
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Fig. 6C. Effect of application of enterosorbent under the code Сrim_04 on the level of urea in the blood 
of rats when modeling acute toxic damage to the liver (mmol/l). 
Note: ** – p <0.05 – in comparison with the control; * – p <0.05 – in comparison with intact 
 
 
Fig. 6D. Effect of the use of enterosorbent under the code Сrim_04 on the level of creatinine in the blood 
of rats when modeling acute toxic damage to the liver (μmol/l). 
Note: ** – p <0.05 – in comparison with the control; * – p <0.05 – in comparison with intact 
 
This effect of enterosorbent Crim_04 was 
dose-dependent. The enterosorbent Crim_04 
showed the highest result in doses of 770 mg/kg 
and 1500 mg/kg without increasing the effect with 
further dose build-up. Biochemical indices of 
experimental animals when using enterosorbent 
under the Crim_04 cipher are not significantly 
different from those in the group of animals that 
received the Smecta preparation. 
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Fig. 6E. Effect of application of enterosorbent under the code Сrim_04 on the level of total bilirubin in 
the blood of rats when modeling acute toxic damage to the liver (μmol/l). 
Note: ** – p <0.05 – in comparison with the control; * – p <0.05 – in comparison with intact 
 
A normal population of hepatic cells and 
tissue homogeneity are shown in a typical liver 
sample from a group of intact animals (Fig. 7A). 
In liver preparations of rats receiving CTC and 
LPS, the presence of small-focal necrosis of 
hepatocytes, signs of large droplet fatty 
hepatocyte, granular dystrophy of hepatocytes, 
some hepatocytes had the appearance of cricoid 
cells. The fullness of the blood vessels of the liver, 
moderate expansion of the veins of the portal 
tracts was registered (Fig. 7B). 
 
 
Fig. 7. Morphological examination of liver tissue (microphotography × 100). 
Note: A – group of intact animals; B – control group; C – enterosorbent under the cipher of Crim_04 in a dose of 
385 mg/kg; D – enterosorbent under the code number Crim_04 in a dose of 770 mg/kg;  
E – enterosorbent under the cipher of Crim_04 in a dose of 1500 mg/kg; F – the drug "Smecta"  
in a dose of 770 mg/kg 
А  B C 
D E F 
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In groups of animals treated with 
montmorillonite-based enterosorbent under the 
laboratory code Crim_04 at doses of 770 mg/kg and 
1500 mg/kg, necrotic changes were not revealed. 
The structure of the liver retained normal 
histoarchitectonics. Hepatocytes are located 
typically. In some preparations, signs of small 
droplet fatty degeneration of hepatocytes. 
Determined moderate plethora of blood vessels of 
the liver. Portal tracts are not expanded  
(Fig. 7D, 7E). 
In the morphometric analysis of liver tissue, 
it was found that when modeling acute toxic 
damage to the liver with 50% oil carbon 
tetrachloride, the volume of hepatocytes 
increased due to large-droplet fatty degeneration, 
as a result of which the nuclear-cytoplasmic index 
(NCI) in the control group decreased 
significantly. Thus, in the control group, the NCI 
was 0.14±0.001 vs. 0.32±0.001 for the group of 
intact animals. When the enterosorbent is used 
under the Crim_04 cipher, there is an increase in 
the parameters of the NCI, reaching a level of 
0.28±0.001 in the group of animals taking 
Crim_04 at a dose of 1500 mg/kg. 
When using enterosorbent under the 
laboratory code Crim_04 on the model of chronic 
CTC-induced toxic liver damage, the activity of 
AsAT and AlAT in the blood plasma of animals 
decreased, the de Ritis coefficient increased from 
1.6 to 2.3. Similarly, the introduction of 
enterosorbent under the code Crim_04 caused a 
decrease in the activity of alkaline phosphatase, 
levels of urea, creatinine and total bilirubin in the 
blood plasma of experimental animals. This effect 
of enterosorbent Crim_04 was dose-dependent. 
The enterosorbent Crim_04 showed the highest 
result in doses of 770 mg/kg and 1500 mg/kg 
without increasing the effect with further dose 
build-up. Biochemical indices of experimental 
animals when using enterosorbent under the 
Crim_04 cipher are not significantly different 
from those in the group of animals that received 
the Smecta preparation. 
The study of the dose-dependent nature of 
the effectiveness of the use of enterosorbent on 
the basis of montmorillonite under the 
laboratory code Crim_04 in the simulation of 
acute L-arginine-induced pancreatitis. 
The dose-dependent nature of the influence 
of enterosorbent on the basis of montmorillonite 
under the laboratory cipher of Crim_04 on the 
biochemical parameters of blood serum of rats in 
comparison with the "Smecta" preparation against 
the background of modeling of acute L-arginine-
induced pancreatitis is presented in the table 1. It 
has been established that the montmorillonite-
based enterosorbent under the laboratory cipher 
Crim_04 has a dose-dependent effect when 
modeling acute L-arginine-induced pancreatitis in 
rats. This is expressed in a decrease in the activity 
of amylase, AsAt, AlAT, a decrease in serum 
triglyceride levels and glucose in rats. 
Table 1 
Influence of enterosorbent under the cipher of Crim_04 in comparison with the "Smecta" preparation on 
the biochemical parameters of blood of rats against the background of modeling of acute L-arginine-induced 
pancreatitis (M±m; n=10) 
 
A drug 
Amylase 
(U/l) 
AsAt 
(U/l) 
AlAt 
(U/l) 
TG 
(mmol/l) 
Glucose 
(mmol/l) 
Intact 215±3 121±1 60±0,9 1.0±0.1 5.3±0.7 
L-arginine 1834±12* 521±6* 115±2* 2.9±0.3* 13.5±1.0* 
L-arginine + 
Crim_04 385 mg / kg 
1320±14** 325±5** 94±4** 2.1±0.1** 10.9±2.2** 
L-arginine + 
Crim_04 770 mg / kg 
836±4a 182±4a 79±2a 1.4±0.2a 8.5±1.1a 
L-arginine + 
Crim_04 1500 mg / 
kg 
801±3a 171±2a 76±2a 1.2±0.1a 7.9±1.2a 
L-arginine + 
Smecta 770 mg / kg 
852±5** 189±4** 77±3** 1.3±0.1** 8.8±1.4** 
Note: * – for p <0.05 in comparison with the intact group; ** – at p <0.05 in comparison with the control group; a – 
at p <0.05 in comparison with Crim_04 in a dose of 880 mg/kg. 
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This indicates a decrease in inflammation of 
the pancreas. In this case, the effect of 
enterosorbent based on montmorillonite under the 
Crim_04 cipher was dose-dependent, most 
pronounced at a dose of 770 mg/kg without 
improvement in the parameters with further dose 
build-up. This is also confirmed by histological 
examination (Fig. 8). 
 
 
Fig. 8. Morphological examination of pancreatic tissue (microphoto × 100). 
Note: A – group of intact animals; B – control group; C – enterosorbent under the cipher of Crim_04 in a dose of 
1500 mg/kg 
 
In histological study, it was found that with the 
induction of acute pancreatitis by intraperitoneal 
administration of L-arginine at a dose of 1.5 mg / kg 
in pancreatic tissue, pronounced edema, focal 
necrosis of the acinocytes, islets of Langerhans of 
different calibers (Fig. 8B). In the group of intact 
animals, the pancreas retained a typical structure 
(Fig. 8A). 
When using enterosorbent under the code 
Crim_04 at a dose of 385 mg / kg pancreas was 
moderately edematous, small foci of necrosis of 
acinocytes, islets of Langerhans of different 
calibers are determined. 
In doses of 770 mg / kg and 1500 mg / kg 
enterosorbent under the cipher of Crim_04 
prevented necrosis of the acinocytes, small 
puffiness of the pancreatic tissue, the islets of 
Langerhans of the usual structure is determined 
(Fig. 8C). 
Discussion 
In carrying out complex studies of the 
pharmacological activity of enterosorbent under 
the laboratory cipher of Crim_04, in the modeling 
of serotonin-induced diarrhea, MgSO4-induced 
diarrhea, diarrhea induced by castor oil, isolated 
gut loop, acute and chronic liver damage, and L-
arginine induced acute pancreatitis, that the 
enterosorbent under the cipher Crim_04 has a 
dose-dependent antidiarrheal, detoxification 
activity, a high sorption for enterotoxin of E.coli 
activity w, high therapeutic efficacy in 
experimental pancreatitis, most pronounced at a 
dose of 3320 mg/kg. 
Taking into account the results obtained in 
the work, it is possible to determine the 
recommendations and outline the prospects for 
further work in this area. 
In the course of the study, it was shown that 
the enterosorbent based on montmorillonite 
Crim_04 has a high antidiarrheal, detoxification 
activity, therapeutic efficacy in experimental 
acute pancreatitis, showing a clear dose-
dependent effect. 
The data obtained in the course of the study 
on the pharmacological activity of the 
enterosorbent under the laboratory cipher of 
Crim_04 gives broad prospects for further study 
of this pharmacological agent. Enterosorbent 
based on montmorillonite Crim_04 can be 
recommended for further clinical effectiveness 
and safety for the treatment of acute diarrhea of 
various etiologies, diseases accompanied by 
endotoxicosis, exogenous intoxications. 
The data obtained in the course of the study 
on the pharmacological activity of the 
enterosorbent under the laboratory cipher of 
Crim_04 gives broad prospects for further study 
of this pharmacological agent. Enterosorbent 
Crim_04 can be recommended for further 
preclinical study of pharmacological activity in 
models of acute gastric ulcers, Crohn's disease, 
acute and chronic intoxications with salts of 
heavy metals, intoxications with mycotoxins and 
bacterial enterotoxins. Enterosorbent based on 
montmorillonite Crim_04 can be recommended 
for further clinical effectiveness and safety for the 
C A B 
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treatment of acute diarrhea of various etiologies, 
diseases accompanied by endotoxicosis, 
exogenous intoxications. 
It is promising to conduct further preclinical 
studies of enterosorbent based on montmorillonite 
under the laboratory code Crim_04 in modeling 
acute gastric ulcers, Crohn's disease, acute 
intoxications with heavy metal salts, mycotoxins, 
bacterial toxins, as well as complex preclinical 
toxicological safety tests and clinical studies of 
enterosorbent based on montmorillonite under the 
laboratory code Crim_04. 
Conclusions 
1. Enterosorbent based on montmorillonite 
under laboratory code Crim_04 on the results of 
the study of acute toxicity is low toxic 
pharmacological agent and refers to substances 
hazard class IV. At a dose of 8500 mg/kg, the 
enterosorbent does not cause lethality and 
changes in the functional state in mice. 
2. Enterosorbent based on montmorillonite 
under laboratory code Crim_04 possesses a dose-
dependent Antidiarrhoeal activity in the 
simulation serotonin-induced diarrhea, MgSO4-
induced diarrhea, diarrhea induced by castor oil. 
This is expressed in an increase in the onset of 
diarrhea, a decrease in the number of bowel 
movements and a decrease in the amount of fluid 
in the stool. At the same time, the prevention of 
the development of mucosal villus hypotrophy 
and crypt hypertrophy was detected 
morphometrically. 
3. In the simulation, the isolated loop 
intestine enterosorbent based on montmorillonite 
possesses a cipher Crim_04 dose dependent 
sorption activity in relation to the heat labile 
enterotoxin of E.coli cholera, which is manifested 
in the prevention of exposure to toxin intestinal 
wall and, consequently, inhibition of fluid 
exudation into the gut lumen. 
4. Enterosorbent based on montmorillonite 
under laboratory code Crim_04 disintoxicational 
possesses a dose-dependent effect in models of 
acute and chronic liver injury, which manifests 
itself in significant reduction in the activity of the 
liver enzymes, as well as levels of urea, 
creatinine, and total bilirubin. The activity of 
enterosorbent is confirmed by morphological 
examination of liver tissue. 
5. Enterosorbent based on montmorillonite 
under cipher Crim_04 possesses a dose-
dependent therapeutic efficacy in experimental L-
arginine-induced pancreatitis, it reduces the 
activity of amylase, transaminases, triglycerides, 
blood glucose serum. The efficacy of 
enterosorbent was confirmed by histological 
examination of pancreatic tissue. 
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